Literature DB >> 3940818

Fulminant hepatitis A in chronic HBV carrier.

J Y Wang, S D Lee, Y T Tsai, K J Lo, B N Chiang.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3940818     DOI： 10.1007/bf01347921

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.199


× No keyword cloud information.
  7 in total

1.  Effect of short-term prednisone therapy on aminotransferase levels and hepatitis B virus markers in chronic type B hepatitis.

Authors:  J Rakela; A G Redeker; B Weliky
Journal:  Gastroenterology       Date:  1983-05       Impact factor: 22.682

2.  The clinical course of acute type A hepatitis in chronic HBsAg carriers--a report of 3 cases.

Authors:  L A Viola; I G Barrison; J C Coleman; I M Murray-Lyon
Journal:  Postgrad Med J       Date:  1982-02       Impact factor: 2.401

3.  Intercurrent hepatitis A in B viral hepatitis.

Authors:  R A Wilson
Journal:  JAMA       Date:  1981-06-26       Impact factor: 56.272

4.  Acute type A hepatitis in three patients with chronic HBV infection.

Authors:  C Conteas; H Kao; J Rakela; B Weliky
Journal:  Dig Dis Sci       Date:  1983-08       Impact factor: 3.199

5.  Antiviral treatment of chronic hepatitis B virus infection. I. Changes in viral markers with interferon combined with adenine arabinoside.

Authors:  G H Scullard; R B Pollard; J L Smith; S L Sacks; P B Gregory; W S Robinson; T C Merigan
Journal:  J Infect Dis       Date:  1981-06       Impact factor: 5.226

6.  Hepatitis A infection in chronic carriers of hepatitis B virus.

Authors:  R Zachoval; M Roggendorf; F Deinhardt
Journal:  Hepatology       Date:  1983 Jul-Aug       Impact factor: 17.425

7.  Acute type A hepatitis during chronic hepatitis B virus infection: association of depressed hepatitis B virus replication with appearance of endogenous alpha interferon.

Authors:  G L Davis; J H Hoofnagle; J G Waggoner
Journal:  J Med Virol       Date:  1984       Impact factor: 2.327
  7 in total
  5 in total

Review 1.  Preventive care in chronic liver disease.

Authors:  T R Riley; J P Smith
Journal:  J Gen Intern Med       Date:  1999-11       Impact factor: 5.128

2.  Immunogenicity and safety of hepatitis E vaccine in healthy hepatitis B surface antigen positive adults.

Authors:  Ting Wu; Shou-Jie Huang; Feng-Cai Zhu; Xue-Feng Zhang; Xing Ai; Qiang Yan; Zhong-Ze Wang; Chang-Lin Yang; Han-Min Jiang; Xiao-Hui Liu; Meng Guo; Hai-Lian Du; Mun-Hon Ng; Jun Zhang; Ning-Shao Xia
Journal:  Hum Vaccin Immunother       Date:  2013-07-25       Impact factor: 3.452

3.  Seroprevalence of anti-HAV among patients with chronic viral liver disease.

Authors:  Hyun Chin Cho; Seung Woon Paik; Yu Jin Kim; Moon Seok Choi; Joon Hyeok Lee; Kwang Cheol Koh; Byung Chul Yoo; Hee Jung Son; Seon Woo Kim
Journal:  World J Gastroenterol       Date:  2011-01-14       Impact factor: 5.742

4.  Seroprevalence and Molecular Characterisation of Human Hepatitis A virus in Serum Samples of Tunisian Patients with Clinical Symptoms of Viral Hepatitis.

Authors:  Hakima Gharbi-Khelifi; Nabil Ben Salem Abid; Abir Beji; Leila Bhiri; Rafik Harrath; Khira Sdiri; Sylviane Billaudel; Virginie Ferre; Mahjoub Aouni
Journal:  Indian J Virol       Date:  2012-03-25

5.  Preventative care in cholestatic liver disease: Pearls for the specialist and subspecialist.

Authors:  Adnan Malik; Ani A Kardashian; Kais Zakharia; Christopher L Bowlus; James H Tabibian
Journal:  Liver Res       Date:  2019-05-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.